CannaPharmaRX

CPMD

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.00

+0.00 (+15.15%)

Market Cap

$1.3M

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+787.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 74.7M (2021) → 662.5M (2025)

Winston Score History

The full picture

CannaPharmaRX is a small healthcare company focused on developing cannabis-based pharmaceutical products. It works to turn compounds found in the cannabis plant into medicines that could be used to treat medical conditions. The company operates in the specialty pharmaceutical space, where the goal is to move cannabis from a plant into a regulated drug product.

The company earns little to no revenue right now and is in an early development stage, which explains its deeply negative profit margins. It is a very small U.S.-based company with a market cap that rounds to essentially zero, meaning it carries significant financial risk. The biggest challenge facing CannaPharmaRX is that it must successfully develop, test, and gain regulatory approval for its products before it can generate meaningful sales — a process that is expensive, slow, and uncertain for any early-stage drug company.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+19.3% YoY

YoY Growth Rate

Steady revenue growth

EPS Growth

-33.3% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

7.0%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$555 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

CannaPharmaRX is a rare growth stock that's already generating positive cash flow while growing at 19%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-50.1%

Thin — -50.1% gross margin

Profit after running costs

Operating Margin

-137.1%

Losing money on operations — -137.1%

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+24.8%

Fast-growing sales (+24.8% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-94.5%

Burning cash (-94.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial